S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:SYBX

Synlogic (SYBX) Stock Price, News & Analysis

$1.79
+0.01 (+0.56%)
(As of 03/28/2024 ET)
Today's Range
$1.70
$1.85
50-Day Range
$1.72
$3.60
52-Week Range
$1.55
$10.64
Volume
43,940 shs
Average Volume
139,294 shs
Market Capitalization
$20.85 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$65.00

Synlogic MarketRank™ Stock Analysis

Analyst Rating
Hold
2.20 Rating Score
Upside/​Downside
3,531.3% Upside
$65.00 Price Target
Short Interest
Healthy
0.37% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.68mentions of Synlogic in the last 14 days
Based on 13 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.09) to ($3.86) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.51 out of 5 stars

Medical Sector

750th out of 938 stocks

Pharmaceutical Preparations Industry

339th out of 423 stocks

SYBX stock logo

About Synlogic Stock (NASDAQ:SYBX)

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic and immunological diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase II clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine to treat solid tumors and lymphoma. It has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.

SYBX Stock Price History

SYBX Stock News Headlines

“The Stock Market’s Bull Run is Far from Over” -Barrons
Barron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!
Synlogic Adopts Limited Duration Stockholders Rights Plan
Synlogic Adopts Limited Duration Stockholders Rights Plan
“The Stock Market’s Bull Run is Far from Over” -Barrons
Barron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!
Synlogic just downgraded at Chardan, here's why
Why Is Synlogic (SYBX) Stock Down 55% Today?
Synlogic Inc (MIN.MU)
See More Headlines
Receive SYBX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Synlogic and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/19/2024
Today
3/28/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:SYBX
Employees
6
Year Founded
2013

Price Target and Rating

Average Stock Price Target
$65.00
High Stock Price Target
$90.00
Low Stock Price Target
$30.00
Potential Upside/Downside
+3,531.3%
Consensus Rating
Hold
Rating Score (0-4)
2.20
Research Coverage
5 Analysts

Profitability

Net Income
$-57,280,000.00
Net Margins
-1,699.23%
Pretax Margin
-1,698.84%

Debt

Sales & Book Value

Annual Sales
$3.37 million
Book Value
$4.64 per share

Miscellaneous

Free Float
10,714,000
Market Cap
$20.85 million
Optionable
Optionable
Beta
1.09

Social Links

7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Mr. Antoine Awad (Age 43)
    Principal Executive Officer & COO
    Comp: $566.55k
  • Dr. Timothy K. Lu M.D. (Age 43)
    Ph.D., Co-Founder & Member of Scientific Advisory Board
  • Dr. James J. Collins Ph.D. (Age 57)
    Co-Founder & Member of Scientific Advisory Board
  • Ms. Mary Beth Dooley (Age 43)
    Head of Finance and Principal Financial Officer & Principal Accounting Officer
  • Mr. Brendan St. Amant
    General Counsel & Corporate Secretary
  • Mr. Ajay Munshi
    Vice President of Corporate Development
  • Mr. Adam J. Thomas
    Chief People Officer
  • Dr. Caroline B. Kurtz Ph.D.
    Chief Development Officer
  • Ms. Molly Harper (Age 47)
    Chief Business Officer
  • Dr. Neal Sondheimer M.D.
    Ph.D., VP & Head of Clinical

SYBX Stock Analysis - Frequently Asked Questions

Should I buy or sell Synlogic stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Synlogic in the last year. There are currently 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" SYBX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SYBX, but not buy additional shares or sell existing shares.
View SYBX analyst ratings
or view top-rated stocks.

What is Synlogic's stock price target for 2024?

5 analysts have issued 1-year target prices for Synlogic's stock. Their SYBX share price targets range from $30.00 to $90.00. On average, they predict the company's stock price to reach $65.00 in the next year. This suggests a possible upside of 3,531.3% from the stock's current price.
View analysts price targets for SYBX
or view top-rated stocks among Wall Street analysts.

How have SYBX shares performed in 2024?

Synlogic's stock was trading at $3.85 on January 1st, 2024. Since then, SYBX stock has decreased by 53.5% and is now trading at $1.79.
View the best growth stocks for 2024 here
.

When is Synlogic's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our SYBX earnings forecast
.

How were Synlogic's earnings last quarter?

Synlogic, Inc. (NASDAQ:SYBX) issued its earnings results on Tuesday, March, 19th. The biotechnology company reported ($1.71) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.11) by $0.60. The biotechnology company earned $2.77 million during the quarter, compared to the consensus estimate of $2.71 million. Synlogic had a negative net margin of 1,699.23% and a negative trailing twelve-month return on equity of 109.34%.

When did Synlogic's stock split?

Synlogic's stock reverse split on Thursday, September 28th 2023. The 1-15 reverse split was announced on Thursday, September 28th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, September 28th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Synlogic own?
Who are Synlogic's major shareholders?

Synlogic's stock is owned by a number of retail and institutional investors. Top institutional investors include Armistice Capital LLC (11.48%), Vanguard Group Inc. (2.05%), Vanguard Group Inc. (2.05%), Harbor Capital Advisors Inc. (0.33%), Citadel Advisors LLC (0.12%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Antoine Awad, Aoife Brennan and Michael Vangsted Jensen.
View institutional ownership trends
.

How do I buy shares of Synlogic?

Shares of SYBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SYBX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners